Articles

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.

Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs

MilliporeSigma announced the opening of its second Carlsbad, California-based facility, which doubles production capacity to support commercial and industrial manufacturing of viral vectors. 

MilliporeSigma Completes $110-Million Contract Development Manufacturing Facility for Gene Therapy

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

After months of deliberation, Biden plans to appoint cardiologist Robert Califf as FDA commissioner.

Can Califf Bring Clarity and Enhanced Credibility to FDA?

Advanced powder testing is a useful tool to differentiate materials and optimize the supply chain.

Building Robust Specifications Using Powder Testing

Aceto will acquire A&C Bio Buffer, including the company’s custom buffer and chemical blend portfolio.

Aceto Acquires A&C Bio Buffer, Expanding GMP Product Lines in Biopharma

Pharmalex has launched the Biopharma Excellence brand, a new service line that combines the expertise of PharmaLex, ERA Consulting, and Biopharma Excellence.

Pharmalex Launches Major New Service Line, Biopharma Excellence

SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.

SGS Invests in New E&L Laboratory in India

AION Labs will be a first-of-its-kind AI/pharma and computational biology innovation lab aimed at spearheading the adoption of AI technologies and computational science. 

AstraZeneca, Merck KGaA, Pfizer, and Teva Team up with Tech and Investment Leaders to Launch New Biotech Innovation Lab 

This acquisition grants Bionano access to BioDiscovery’s clinical software solution for variant analysis.

Bionano Genomics Acquires BioDiscovery Inc. for $100 Million

The collaboration between Intellia and SparingVision will work to develop genomic medicines for ocular diseases.

News